The FDA handed down its Class I label, the most severe recall classification, for Koninklijke Philips NV's PHG ventilators for at-home and clinical use after the devices were found to put users at risk of inhaling or swallowing dangerous pieces of debris.
- Philips initiated the recall in mid-June.
- Patients and healthcare providers using the company's continuous and non-continuous ventilators, including CPAP and BiPAP machines to treat sleep apnea, are asked to stop using the devices immediately and contact Philips to replace the component.
- Polyester-based polyurethane (PE-PUR) foam built into Philips' ventilators to help reduce sound and vibrations is the root issue.
- Over time the foam can potentially break down, sending specks of black debris and dangerous chemicals into the air pathway.
- If inhaled or swallowed, the particles can cause severe irritation of the skin, eyes, and respiratory tract, asthma, and nausea, among other reactions.
- They can also potentially damage internal organs like the kidney and liver or have other toxic, carcinogenic effects.
- According to the recall notice, more than 1,200 complaints have been filed regarding the issue so far.
- At least 100 injuries are linked to the foam particles.
- Philips will replace the PE-PUR foam sound abatement component with the new silicone foam sound abatement component in the affected devices to correct in the field.
- Price Action: PHG shares are up 1.86% at $47.98 during the market session on the last check Friday.
- Related content: Benzinga's Full FDA Calendar.
- Photo via Wikimedia Commons
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in